Abstract:BACKGROUND AND OBJECTIVE:Cisplatin-resistance in lung cancer cells is general in clinic, hence it is significant to investigate the mechanisms of cisplatin-resistant and develop new methods of reversing drug-resistance. Recent researches showed that miRNA could regulate cell growth, apoptosis, migration and invasion even in drug therapy in cancer by its target gene. The aim of this study is to investigate the effects and molecular mechanisms of miR-503 on reversing the cisplatin-resistance in lung cancer DDP-resistant cell line A549/DDP.METHODS:MTS assay was employed to determine the effect of miR-503 on A549/DDP' sensitivity to cisplatin. Apoptosis rate and intracellular concentration of rhodamine-123 (Rh-123) were determined by flow cytometry, the expression of multi-drugs resistant proteins MDR1 and MRP1, ERCC1, RhoE, Survivin and Bcl-2 were determined by Western blot and real time PCR. The phosphorylation of Akt was analyzed by Western blot, the transcriptional activities of NF-κB and AP-1 were detected by dual-luciferase reporter gene systems.RESULTS:MiR-503 was able to increase the cisplatin sensitivity of A549/DDP. After treatment with miR-503, the reverse folds (RF) to cisplatin was 2.48 fold, the intracellular level of Rh-123 was 2.49 fold, the apoptosis rate was 10.3 fold, the expressions of several drug-resistant related proteins, such as MDR1, MRP1, ERCC1, Survivin and Bcl-2 were downregulated significantly, as shown by WB, in contrast, the level of RhoE was elevated, the mRNA epression of MDR1 was 18.5%, the mRNA epression of MRP1 was 22.3%, the mRNA epression of ERCC1 was 18.6%, the mRNA epression of Survivin was 42.8%, the mRNA expression of Bcl-2 was 68.1%, the mRNA epression of RhoE was 206.5%, in addition, the phosphorylation of Akt decreased and transcriptional activities of NF-κB was 53.7%, AP-1 was 47.4% compared with control group.CONCLUSIONS:MiR-503 was able to reverse the cisplatin resistance of A549/DDP. MiR-503 processed this kind of effect by inhibiting the drug efflux, downregulating the expression of drug-resistant related proteins and promoting cell apoptosis.

Mir‑383 Increases the Cisplatin Sensitivity of Lung Adenocarcinoma Cells Through Inhibition of the RBM24‑mediated NF‑κB Signaling Pathway

Mir-488 Inhibits Proliferation And Cisplatin Sensibility In Non-Smallcell Lung Cancer (Nsclc) Cells By Activating The Eif3a-Mediated Ner Signaling Pathway

miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin

Mir-324-3p Reverses Cisplatin Resistance by Inducing GPX4-mediated Ferroptosis in Lung Adenocarcinoma Cell Line A549

Mir-503 Regulates the Resistance of Non-Small Cell Lung Cancer Cells to Cisplatin by Targeting Bcl-2.

MiR-192 Confers Cisplatin Resistance by Targeting Bim in Lung Cancer

Mir‑144‑3p Regulates the Resistance of Lung Cancer to Cisplatin by Targeting Nrf2.

Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5

Mir-133B Reverses Cisplatin Resistance by Targeting GSTP1 in Cisplatin-Resistant Lung Cancer Cells.

MiR-375 promotes cisplatin sensitivity of lung adenocarcinoma

DNA Damage Responsive Mir-33B-3p Promoted Lung Cancer Cells Survival and Cisplatin Resistance by Targeting P21waf1/cip1

The Reversing and Molecular Mechanisms of Mir-503 on the Drug-resistance to Cisplatin in A549/DDP Cells

Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1

Mir-340 Reverses Cisplatin Resistance Of Hepatocellular Carcinoma Cell Lines By Targeting Nrf2-Dependent Antioxidant Pathway

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells

miR-140-3p enhances cisplatin sensitivity and attenuates stem cell-like properties through repressing Wnt/β-catenin signaling in lung adenocarcinoma cells

MiR-5100 Increases the Cisplatin Resistance of the Lung Cancer Stem Cells by Inhibiting the Rab6

Cisplatin-induced Epigenetic Activation of Mir-34A Sensitizes Bladder Cancer Cells to Chemotherapy

Author Correction: MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway

Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP)

microRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status.